Erlotinib or Observation in Treating Patients Who Have Undergone First-Line Chemotherapy for Ovarian Cancer, Peritoneal Cancer, or Fallopian Tube Cancer

NCT00263822 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

835

Enrollment

NETWORK

Sponsor class

Conditions

Fallopian Tube Cancer
Ovarian Cancer
Primary Peritoneal Cavity Cancer

Interventions

DRUG: erlotinib hydrochloride

Sponsor

European Organisation for Research and Treatment of Cancer - EORTC